Expert forum

Hot spots in diagnosis of malignant melanoma

Expand
  • 1. Department of Dermatology, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan 430022, China
    2. Department of Dermatology, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan 430014, China

Received date: 2023-06-03

  Online published: 2023-11-17

Abstract

The global incidence of melanoma increased from 2.01/ 100 000 in 1990 to 3.75/100 000 in 2019. The incidence and mortality rate of malignant melanoma in China is lower than that of the global average, but in recent years, its incidence rate has increased (3% to 5%). Malignant melanoma is the fastest growing malignant tumor in China, and new melanoma patients reach 20 000 to 30 000 cases every year. Melanoma is prone to invasion and metastasis, and the 5-year survival rate of stage IV patients is only 4.6%. Early diagnosis and treatment can greatly improve the prognosis of patients with malignant melanoma. At present, the hot spots in the diagnosis of malignant melanoma include visual aid, artificial intelligence-assisted diagnosis, histological diagnosis and differential diagnosis. Visual AIDS can be used to screen for melanoma, and dermoscopy and skin confocal technology (CT) can diagnose melanoma with sensitivity of 61% and 100%, respectively. AI based diagnosis of malignant melanoma is more accurate than that of artificial intelligence alone or doctors, and can improve the diagnosis accuracy of malignant melanoma from 55.6% to 75.0%. With the continuous progress of second-generation sequencing technology in histology diagnosis, there is still a lack of objectively and highly repeatable immunohistochemical markers applicable to all melanomas. However, with the development of melanoma genomics research, BRAF V600E and NRAS mutations have been applied in clinical diagnosis, treatment and prognosis assessment. Malignant melanoma is highly invasive, and many patients are in the advanced stage when diagnosed. Therefore, the diagnosis and treatment of melanoma in China should pay attention to the multidisciplinary diagnosis and treatment team model, and promote the diagnosis and treatment principles and guidelines based on multidisciplinary consensus.

Cite this article

WU Nanming, LI Jun, TAO Juan . Hot spots in diagnosis of malignant melanoma[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(03) : 215 -220 . DOI: 10.16150/j.1671-2870.2023.03.02

References

[1] WANG J Y, WANG E B, SWETTER S M. What is melanoma?[J]. JAMA. 2023, 329(11):948.
[2] ARNOLD M, SINGH D, LAVERSANNE M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040[J]. JAMA Dermatol, 2022, 158(5):495-503.
[3] BAI R, HUANG H, LI M, et al. Temporal trends in the incidence and mortality of skin malignant melanoma in china from 1990 to 2019[J]. J Oncol, 2021:9989824.
[4] LIN L, LI Z, YAN L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019[J]. J Hematol Oncol, 2021, 14(1):197.
[5] CUI C, WANG X, LIAN B, et al. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study[J]. J Immunother Cancer, 2022, 10(4):e004307.
[6] PARRA L M, WEBSTER R M. The malignant melanoma market[J]. Nat Rev Drug Discov, 2022. 21(7):489-490.
[7] DESSINIOTI C, GELLER A C, STRATIGOS A J. A review of nevus-associated melanoma: What is the evidence?[J]. J Eur Acad Dermatol Venereol, 2022, 36(11):1927-1936.
[8] RIGEL D S, RUSSAK J, FRIEDMAN R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs[J]. CA Cancer J Clin, 2010, 60(5):301-316.
[9] ILYAS M, COSTELLO C M, ZHANG N, et al. The role of the ugly duckling sign in patient education[J]. J Am Acad Dermatol, 2017, 77(6):1088-1095.
[10] CABRERA R, RECULE F. Unusual clinical presentations of malignant melanoma: a review of clinical and histologic features with special emphasis on dermatoscopic findings[J]. Am J Clin Dermatol, 2018, 19(Suppl 1):15-23.
[11] XIONG Y Q, MA S J, MO Y, et al. Comparison of dermoscopy and reflectance confocal microscopy for the diagnosis of malignant skin tumours: a meta-analysis[J]. J Cancer Res Clin Oncol, 2017, 143(9):1627-1635.
[12] ARGENZIANO G, KITTLER H, FERRARA G, et al. Slow-growing melanoma: a dermoscopy follow-up study[J]. Br J Dermatol, 2010, 162(2):267-273.
[13] TEJERA-VAQUERIZO A, ARIAS-SANTIAGO S, NAGORE E, et al. Defining the dermoscopic characteristics of fast-growing cutaneous melanomas[J]. Melanoma Res, 2015, 25(3):269-272.
[14] DEINLEIN T, ARZBERGER E, ZALAUDEK I, et al. Dermoscopic characteristics of melanoma according to the criteria "ulceration" and "mitotic rate" of the AJCC 2009 staging system for melanoma[J]. PLoS One, 2017, 12(4):e0174871.
[15] YU Z, NGUYEN J, NGUYEN T D, et al. Early melanoma diagnosis with sequential dermoscopic images[J]. IEEE Trans Med Imaging, 2022, 41(3):633-646.
[16] ELSHOT Y S, TIO D C K S, VAN HAERSMA-DE WITH A S E, et al. Lentigo maligna (melanoma): a systematic review and meta-analysis on surgical techniques and presurgical mapping by reflectance confocal microscopy[J]. J Eur Acad Dermatol Venereol, 2023, 37(5):871-883.
[17] CONDORELLI A G, FARNETANI F, CIARDO S, et al. Dynamic dermoscopic and reflectance confocal microscopic changes of melanocytic lesions excised during follow up[J]. J Am Acad Dermatol, 2022, 86(5):1049-1057.
[18] VERA J, LAI X, BAUR A, et al. Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence[J]. Brief Bioinform, 2022, 23(6):bbac433.
[19] ESTEVA A, KUPREL B, NOVOA R A, et al. Dermatologist-level classification of skin cancer with deep neural networks[J]. Nature, 2017, 542(7639):115-118.
[20] SOENKSEN L R, KASSIS T, CONOVER S T, et al. Using deep learning for dermatologist-level detection of suspicious pigmented skin lesions from wide-field images[J]. Sci Transl Med, 2021, 13(581):eabb3652.
[21] PHILLIPS M, MARSDEN H, JAFFE W, et al. Assessment of accuracy of an artificial intelligence algorithm to detect melanoma in images of skin lesions[J]. JAMA Netw Open, 2019, 2(10):e1913436.
[22] ROZEMAN E A, HOEFSMIT E P, REIJERS I L M, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage Ⅲ melanoma[J]. Nat Med, 2021, 27(2):256-263.
[23] HAENSSLE H A, FINK C, SCHNEIDERBAUER R, et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists[J]. Ann Oncol, 2018, 29(8):1836-1842.
[24] ANDTBACKA R H, GERSHENWALD J E. Role of sentinel lymph node biopsy in patients with thin melanoma[J]. J Natl Compr Canc Netw, 2009, 7(3):308-317.
[25] KASHANI-SABET M. Molecular markers in melanoma[J]. Br J Dermatol, 2014, 170(1):31-35.
[26] DANKORT D, CURLEY D P, CARTLIDGE R A, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma[J]. Nat Genet, 2009, 41(5):544-552.
[27] TEIXIDO C, CASTILLO P, MARTINEZ-VILA C, et al. Molecular markers and targets in melanoma[J]. Cells, 2021, 10(9):2320.
[28] Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma[J]. Cell, 2015, 161(7):1681-1696.
[29] GIBNEY G T, MESSINA J L, FEDORENKO I V, et al. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma[J]. Nat Rev Clin Oncol, 2013, 10(7):390-399.
[30] RANDIC T, KOZAR I, MARGUE C, et al. NRAS mutant melanoma: towards better therapies[J]. Cancer Treat Rev, 2021, 99:102238.
[31] YEH I, BUSAM K J. Spitz melanocytic tumours - a review[J]. Histopathology, 2022, 80(1):122-134.
[32] RAGHAVAN S S, PETERNEL S, MULLY T W, et al. Spitz melanoma is a distinct subset of spitzoid melanoma[J]. Mod Pathol, 2020, 33(6):1122-1134.
[33] MARQUES P C, DINIZ L M, SPELTA K, et al. Desmoplastic melanoma: a rare variant with challenging diagnosis[J]. An Bras Dermatol, 2019, 94(1):82-85.
[34] MCCARTHY S W, SCOLYER R A, PALMER A A. Desmoplastic melanoma: a diagnostic trap for the unwary[J]. Pathology, 2004, 36(5):445-451.
[35] DEWANE M E, KELSEY A, OLIVIERO M, et al. Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma[J]. J Am Acad Dermatol, 2019, 81(3):823-833.
[36] MUINONEN-MARTIN A J, O'SHEA S J, NEWTON-BISHOP J. Amelanotic melanoma[J]. BMJ, 2018, 360:k826.
Outlines

/